Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TNXP 
Tonix Pharmaceuticals Holding Corp (TNXP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TNXP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $61.67
1 Year Target Price $61.67
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 256.69M USD | Price to earnings Ratio 0.1 | 1Y Target Price 61.67 |
Price to earnings Ratio 0.1 | 1Y Target Price 61.67 | ||
Volume (30-day avg) 2 | Beta 2.1 | 52 Weeks Range 6.76 - 95.00 | Updated Date 06/30/2025 |
52 Weeks Range 6.76 - 95.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 356.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -660.93% |
Management Effectiveness
Return on Assets (TTM) -27.59% | Return on Equity (TTM) -91.44% |
Valuation
Trailing PE 0.1 | Forward PE - | Enterprise Value 125466066 | Price to Sales(TTM) 25.56 |
Enterprise Value 125466066 | Price to Sales(TTM) 25.56 | ||
Enterprise Value to Revenue 12.5 | Enterprise Value to EBITDA 0.94 | Shares Outstanding 7357200 | Shares Floating 7320715 |
Shares Outstanding 7357200 | Shares Floating 7320715 | ||
Percent Insiders 0.05 | Percent Institutions 7.03 |
Analyst Ratings
Rating 2 | Target Price 61.67 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tonix Pharmaceuticals Holding Corp
Company Overview
History and Background
Tonix Pharmaceuticals Holding Corp. was founded in 2007. It focuses on developing pharmaceutical products for central nervous system (CNS) disorders and immunological conditions. Its evolution has centered on advancing its pipeline through clinical trials.
Core Business Areas
- CNS Disorders: Development of treatments for conditions like fibromyalgia, PTSD, and depression.
- Immunological Conditions: Developing therapies targeting transplant rejection and other immune-related diseases.
Leadership and Structure
The leadership team includes a CEO, CFO, and Chief Scientific Officer, with a structure typical of a publicly traded pharmaceutical company, including a board of directors.
Top Products and Market Share
Key Offerings
- TNX-102 SL (sublingual cyclobenzaprine): This is the company's most advanced investigational product for treating fibromyalgia. Currently under review. There is no current market share. Competitors include Lyrica (Pfizer), Cymbalta (Eli Lilly), and Savella (Allergan).
- TNX-1900: TNX-1900 (intranasal potentiated oxytocin) is a potential treatment for Prader-Willi syndrome. No current market share. Competitors are limited due to the orphan nature of the disease; however, potential competitors could include off-label use of other psychiatric medications.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant R&D investment required. It is regulated by the FDA.
Positioning
Tonix is a clinical-stage pharmaceutical company focused on niche CNS and immunological markets. Their competitive advantage would depend on successful FDA approvals of their drugs.
Total Addressable Market (TAM)
The total addressable market for CNS disorders is in the billions of dollars annually. Tonix's positioning hinges on capturing a portion of these markets with their novel therapies.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in pipeline
- Focus on underserved medical needs
- Experienced management team
Weaknesses
- Limited revenue stream (clinical stage)
- High cash burn rate
- Dependence on successful clinical trials and FDA approval
- Significant debt
Opportunities
- FDA approval of TNX-102 SL
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- PFE
- ABBV
Competitive Landscape
Tonix faces significant competition from established pharmaceutical companies with greater resources and approved products. Its competitive advantage lies in its novel drug candidates and focus on underserved markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is non-existent as Tonix is still in the development phase.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and regulatory approvals. Analyst projections vary widely based on pipeline success.
Recent Initiatives: Recent initiatives include advancing TNX-102 SL through the regulatory process and exploring partnerships for other pipeline candidates.
Summary
Tonix Pharmaceuticals is a high-risk, high-reward clinical-stage company. Its potential hinges on the success of its pipeline drugs, especially TNX-102 SL. The company faces challenges related to funding, regulatory approvals, and competition. It needs to focus on strengthening its financial position and successfully navigating clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Financial News Outlets (e.g., Yahoo Finance, Bloomberg)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The pharmaceutical industry is inherently risky, and financial performance can vary significantly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tonix Pharmaceuticals Holding Corp
Exchange NASDAQ | Headquaters Chatham, NJ, United States | ||
IPO Launch date 2012-05-10 | Co-Founder, President, CEO & Chairman Dr. Seth Lederman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.tonixpharma.com |
Full time employees 81 | Website https://www.tonixpharma.com | ||
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.